Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg/m2 of melphalan in multiple myeloma: Results of a pilot study including biological aspects

Bone Marrow Transplantation

Volumn 36, Issue 9, 2005, Pages 771-779

  Rossi, J F ^a   Fegueux, N ^a   Lu, Z Y ^b   Legouffe, E ^a   Exbrayat, C ^a   Bozonnat, M C ^c   Navarro, R ^a   Lopez, E ^a   Quittet, P ^a   Daures, J P ^c   Rouille V ^a   Kanouni, T ^a   Widjenes, J ^d   Klein, B ^b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

^c Laboratoire de Biostatistique   (France)

^d Diaclone   (France)

Author keywords

Anti interleukin 6; Autologous transplantation; Multiple myeloma

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CEFPIROME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MELPHALAN; NETILMICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG DOSE REGIMEN; DRUG FEVER; DRUG USE; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; INFECTION; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; PILOT STUDY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPTICEMIA; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PILOT PROJECTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 27744520953     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705138     Document Type: Article

References (48)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
2. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
4. Attal M, Harousseau JL, Facon T et al. InterGroupe Francophone du Myelome. single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
5. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma final: Analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731-735.
6. Sieghel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autologous transplantation for multiple myeloma. Blood 1999; 93: 51-54.
7. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
8. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
9. Goldschmidt H, Egerer G, Ho AD. Autologous and allogenic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2000; 25 (Suppl 2): S25-S26.
10. Rossi JF, Legouffe E, Fegueux N et al. Autologous transplantation (AT) of CD34+ peripheral blood progenitor cells (PBPC) after double (D) high dose chemotherapy (HDC) in multiple myeloma (MM) is followed by severe immunodeficiency (ID) and high production of interleukin-6 (IL-6) related-C Reactive Protein (CRP) requiring additive immunotherapy (IT). Blood 1996; 88 (Suppt1): 132a (abstract 516).
11. Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95: 2234-2239.
12. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
13. Kawano M, Hirano T, Matsuda T et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83-87.
14. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in multiple myeloma. Blood 1995; 85: 863-872.
15. Klein B, Zhang XG, Jourdan M et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
16. Klein B, Zhang XG, Jourdan M et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1990; 1: 193-201.
17. Zhang XG, Gaillard JP, Robillard N et al. Reproducible obtaining myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663.
18. Portier M, Rajzbaum G, Zhang XG et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21: 1759-1762.
19. Greipp P, Leong T, Benett JM et al. Plasmablastic morphology, an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E 9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501-2507.
20. Stasi R, Brunetti M, Parma A et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998; 82: 1860-1866.
21. Klein B, Widjenes J, Zhang XG et al. Murine anti-IL-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
22. Bataille R, Barlogie B, Lu ZY et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-691.
23. Lu ZY, Brailly H, Rossi JF et al. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine 1993; 5: 578-582.
24. Lu ZY, Brailly H, Wijdenes J et al. Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86: 3124-3131.
25. Blay JY, Rossi JF, Widjenes J, Menetrier-Caux C. Role of interleukin-6 in the paraneoplastic syndrome associated with renal cell carcinoma. Int J Cancer 1997; 72: 424-430.
26. Frassanito MA, Cussmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-489.
27. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin-6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-4639.
28. Mizutani Y, Bonavida B, Koishihara Y et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995; 55: 590-596.
29. Klein B, Brailly H. Cytokine-binding proteins: Stimulating antagonists. Immunol Today 1995; 16: 216-220.
30. Montero-Julian F, Klein B, Gautherot E, Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995; 85: 917-924.
31. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European bone Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
32. Widjenes J, Clement C, Klein B et al. Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies. Mol Immunol 1991; 28: 1183-1192.
33. Kaplan EL, Meier P. Non parametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457.
34. Steffen M, Durken M, Pichlmeier U et al. Serum interleukin-6 levels during bone marrow transplantation: Impact on transplant-related toxicity and engraftment. Bone Marrow Transplant 1996; 18: 301-307.
35. Veldhuis GJ, Willemse PH, Sleijfer DT et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 1995; 13: 2585-2593.
36. Trickha M, Corringham R, Klein B, Rossi JF. Targetted anti-interleukin-6 monoclonal antibody therapy for cancer: Review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-4665.
37. Beck JT, Hsu SM, Wijdenes J et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602-605.
38. Emilie D, Widjenes J, Gisselbrecht C et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effects on lymphoma growth and on B clinical symptoms. Blood 1994; 84: 2472-2479.
39. Legouffe E, Liautard J, Gaillard JP et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 1994; 98: 323-329.
40. Castell JV, Gomez-Lechon MJ, David M et al. Acute phase response of human hepatocytes: Regulation of acute phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186.
41. Kollet O, Aviram R, Chebath J. The soluble interleukin-6 (IL-6) receptor/ IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+ CD38-/low cells capable of repopulating severe combined immunodeficiency mice. Blood 1999; 94: 923-931.
42. Sun L, Liu X, Qiu L et al. Administration of plasmid DNA expressing human interleukin-6 significantly improves thrombocytopoiesis in irradiated mice. Ann Hematol 2001; 80: 567-572.
43. Kaser A, Brandacher G, Steurer W et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
44. Efferth T, Fabry U, Osieka R. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Anticancer Res 2002; 22: 231-234.
45. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin-6, dexamethasone, doxorubicin and melphalan. Blood 2000; 96: 3175-3180.
46. Tegg EM, Griffiths AE, Lowenthal RM et al. Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 929-933.
47. 2 melphalan followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003-1006.
48. Durie BGM, Salmon SE. A critical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.